NCT00911066已完成1 期
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 6
- 主要终点
- Adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements
研究概览
简要总结
An open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with acute myelogenous leukemia (AML), high-grade myelodysplastic syndrome (MDS). The patient population will consist of adults previously diagnosed with AML including high-grade MDS for which standard curative, life-prolonging treatment does not exist or is no longer effective.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years
- •Have the following diagnosis:
- •AML or ALL (for the dose escalation phase only)including leukemia secondary to prior chemotherapy or resulting from an antecedent hematologic disorder, who have failed to achieve complete response (CR) or who have relapsed after prior therapy and are not candidates for potentially curative treatment.
- •Acute Promyelocytic Leukemia (APL) patients are not eligible
- •AML or ALL patients who are over age 60 and have not received prior therapy are also eligible if they are not candidates for standard induction chemotherapy
- •High-grade MDS, defined as > 10% blasts on bone marrow examination
- •Low-grade MDS, defined as < 10% blasts on bone marrow examination (Schedule B expansion cohort only)
- •Patients who are willing to refrain from donating blood for at least 90 days after their final dose of MLN4924 and (for male patients) willing to refrain from donating semen for at least 4 months after their final dose of MLN4924
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Female patients who are postmenopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse
- •Male patients who agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse
- •Voluntary written consent
- •Suitable venous access
- •Adequate clinical laboratory values during the screening period as specified in the protocol
- •Patients who are on hydroxyurea may be included in the study and may continue on hydroxyurea while participating in this study.
排除标准
- •Female patients who are lactating or have a positive serum pregnancy test during the screening period
- •Any serious medical or psychiatric illness
- •Treatment with any investigational products
- •Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of study drug, except for hydroxyurea
- •Major surgery within 14 days before the first dose of study drug
- •Life-threatening illness unrelated to cancer
- •Clinically uncontrolled central nervous system (CNS) involvement
- •Known human immunodeficiency virus (HIV) positive
- •Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
- •Evidence of uncontrolled cardiovascular conditions as specified in the protocol
- •Diarrhea > Grade 1, based on the NCI CTCAE categorization
- •Systemic treatment with prohibited medications
- •Ongoing anticoagulant therapy (eg, aspirin, Coumadin, heparin) that cannot be held to permit bone marrow sampling
- •Use of acetaminophen, acetaminophen-containing products, and statins are not permitted on the day before dosing, day of dosing, and day after dosing with MLN4924
研究组 & 干预措施
MLN4924
Experimental
干预措施: MLN4924 (Drug)
Azacitidine
Experimental
干预措施: Azacitidine (Drug)
结局指标
主要结局
Adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements
时间窗: 12 months
次要结局
- Pharmacokinetic parameters(12 months)
- Pharmacodynamic effects(12 months)
- Assess disease response(12 months)
- Heart corrected QT intervals(During screening and during Cycle 1, Days 1 and 15)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple MyelomaHematologic MalignanciesMultiple MyelomaLymphomaHodgkin LymphomaNCT00722488Millennium Pharmaceuticals, Inc.56
已完成
1 期
Study of MLN4924 in Adult Patients With Nonhematologic MalignanciesAdvanced Nonhematologic MalignanciesNCT00677170Millennium Pharmaceuticals, Inc.62
已完成
1 期
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase CAdvanced Gastrointestinal MalignanciesNCT01577758Millennium Pharmaceuticals, Inc.41
终止
1 期
A Study for Patients With Acute LeukemiaAcute LeukemiaNCT01214655Eli Lilly and Company33
已完成
1 期
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesAcute Myelogenous LeukemiaNon-Hodgkin LymphomaAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT02543879Forma Therapeutics, Inc.94